Payment overview · 2025
General Payments
$3,480.63
204 reported records · 35 companies
Healthcare provider profile · identity verified
Stanley E. Scheidler, D.O.
Allopathic & Osteopathic Physicians|General Practice · HAMILTON, OH · NPI 1548243900
Verified facts
What the public records show
CMS Open Payments records show Stanley E. Scheidler, D.O. received $3,480.63 in general payments during 2025 across 204 reported records.
ABBVIE INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Otezla, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $528.88 | 15.2% | 46 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $492.44 | 14.2% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $318.42 | 9.2% | 17 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $264.18 | 7.6% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $245.11 | 7.0% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $196.74 | 5.7% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $144.53 | 4.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.52 | 4.1% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $135.86 | 3.9% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $107.30 | 3.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $99.58 | 2.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.28 | 2.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.17 | 2.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.99 | 1.9% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $64.81 | 1.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.28 | 1.8% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $55.33 | 1.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.04 | 1.4% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $42.13 | 1.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.23 | 0.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.67 | 0.8% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $25.71 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.18 | 0.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.85 | 0.7% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $20.35 | 0.6% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.64 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.37 | 0.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.07 | 0.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $17.03 | 0.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $14.94 | 0.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.75 | 0.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $14.34 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.22 | 0.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $13.69 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,480.63 | 204 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $394.84 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $318.42 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $310.10 | 24 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $290.79 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $264.18 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $236.60 | 18 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $224.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $196.74 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $188.71 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $181.48 | 19 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $154.55 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $144.53 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $135.86 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.97 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $99.58 | 5 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $95.08 | 6 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $93.13 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $78.28 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.17 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.17 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.11 | 8 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $64.81 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $55.33 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.04 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.22 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $20.35 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $8.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 32 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 726 | 207 |
| Gabapentin | Gabapentin | 619 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 468 | 136 |
| Lisinopril | Lisinopril | 441 | 126 |
| Omeprazole | Omeprazole | 353 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 96 |
| Furosemide | Furosemide | 319 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 72 |
| Alprazolam | Alprazolam | 293 | 68 |
| Metformin Hcl | Metformin Hcl | 264 | 75 |
| Potassium Chloride | Potassium Chloride | 236 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 65 |
| Losartan Potassium | Losartan Potassium | 217 | 65 |
| Trazodone Hcl | Trazodone Hcl | 211 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 190 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 189 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 187 | 41 |
| Ozempic | Semaglutide | 169 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 167 | 49 |
| Ibuprofen | Ibuprofen | 166 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 40 |
| Eliquis | Apixaban | 144 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 28 |
| Methocarbamol | Methocarbamol | 125 | 40 |
| Clonazepam | Clonazepam | 124 | 31 |
| Meloxicam | Meloxicam | 124 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 36 |
| Montelukast Sodium | Montelukast Sodium | 117 | 41 |
| Ezetimibe | Ezetimibe | 114 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 112 | 23 |
| Carvedilol | Carvedilol | 109 | 37 |
| Ondansetron Odt | Ondansetron | 108 | 40 |
| Mounjaro | Tirzepatide | 104 | 18 |
| Azithromycin | Azithromycin | 100 | 90 |
| Farxiga | Dapagliflozin Propanediol | 100 | 24 |
| Sertraline Hcl | Sertraline Hcl | 100 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 30 |
| Diazepam | Diazepam | 92 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 92 | 29 |
| Tramadol Hcl | Tramadol Hcl | 89 | 30 |
| Glimepiride | Glimepiride | 87 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 20 |
| Simvastatin | Simvastatin | 87 | 28 |
| Spironolactone | Spironolactone | 87 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 30 |
| Mirtazapine | Mirtazapine | 80 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 19 |
| Lorazepam | Lorazepam | 79 | 20 |
| Methylprednisolone | Methylprednisolone | 78 | 66 |
| Clonidine Hcl | Clonidine Hcl | 75 | 22 |
| Meclizine Hcl | Meclizine Hcl | 75 | 23 |
| Celecoxib | Celecoxib | 70 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 13 |
| Baclofen | Baclofen | 60 | 19 |
| Buspirone Hcl | Buspirone Hcl | 59 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 42 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 12 |
| Famotidine | Famotidine | 53 | 15 |
| Linzess | Linaclotide | 53 | 18 |
| Jardiance | Empagliflozin | 51 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Pregabalin | Pregabalin | 50 | 15 |
| Promethazine Hcl | Promethazine Hcl | 50 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 17 |
| Colchicine | Colchicine | 49 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | 14 |
| Dutasteride | Dutasteride | 47 | 12 |
| Fenofibrate | Fenofibrate | 47 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 18 |
| Primidone | Primidone | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 15 |
| Allopurinol | Allopurinol | 42 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Prednisone | Prednisone | 42 | 18 |
| Cephalexin | Cephalexin | 41 | 28 |
| Topiramate | Topiramate | 41 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 34 |
| Donepezil Hcl | Donepezil Hcl | 39 | 16 |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Anastrozole | Anastrozole | 38 | 12 |
| Naproxen | Naproxen | 38 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 25 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 14 |
| Torsemide | Torsemide | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Famciclovir | Famciclovir | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Bumetanide | Bumetanide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Otezla | Apremilast | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,480.63 · 204 records | ABBVIE INC. | AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, FANAPT, FARXIGA, Fibroscan, GEMTESA, HETLIOZ, JARDIANCE, Kerendia, Korlym, LINZESS, LYBALVI, MAVYRET, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, Prolastin-C Liquid, QULIPTA, RECORLEV, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VERQUVO, VIVITROL, VRAYLAR, Wegovy, XYOSTED, YUPELRI, ZAVZPRET, ZEPBOUND, ZTLido, t:slim X2 Insulin Pump with Control-IQ | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error